Original Investigation

Editorial Comment

A Diabetes-Atrial Fibrillation Conundrum: Does Duration Trump Glycemia?^∗

Dr. Bloomgarden has served on the advisory boards for AstraZeneca, Johnson and Johnson, Merck, Boehringer Ingelheim, and Amgen; has served as a consultant for AstraZeneca, Johnson and Johnson, Merck, Novartis, Boehringer Ingelheim, and Amgen; is a shareholder in Baxter International, CVS Caremark, Roche Holdings, St. Jude Medical, Novartis, and Pfizer; and has served on the speakers bureau for Merck, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, and Regeneron. Dr. Bansilal has reported that he has no relationships relevant to the contents of this paper to disclose.

Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.